A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma

被引：0
|
作者：
Huang, Wendy E. [1 ]
Archer, Christine [1 ]
Yip, Desmond [1 ,2 ]
Kanjanapan, Yada [1 ,2 ]
Peters, Geoffrey [1 ,2 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
[2] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324
引用
下载
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [21] REAL-WORLD OUTCOMES OF PATIENTS WITH RESECTED STAGE IIIA MELANOMA TREATED WITH ADJUVANT NIVOLUMAB IN A US COMMUNITY SETTING
    Samlowski, Wolfram
    Chan, Phillip
    Pavlick, Anna
    Moser, Justin
    Robert, Nicholas
    Poreta, Tayla
    Moshyk, Andriy
    Sakkal, Leon
    Palaia, Jennell
    Niehoff, Nicole
    Rajkumar, Jonathan
    Amin, Asim
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A451 - A451
  • [22] Adjuvant Pembrolizumab in Resected Stage III Melanoma Reply
    Eggermont, Alexander M. M.
    Robert, Caroline
    Suciu, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (06): : 593 - 595
  • [23] Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma
    Samlowski, Wolfram
    Silver, Michelle A.
    Hohlbauch, Andriana
    Zhang, Shujing
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Wang, Yunfei
    Sruti, Ila
    Jiang, Ruixuan
    MELANOMA RESEARCH, 2024, 34 (04) : 326 - 334
  • [24] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
    Larkin, James
    Del Vecchio, Michele
    Mandala, Mario
    Gogas, Helen
    Fernandez, Ana M. Arance
    Dalle, Stephane
    Cowey, Charles Lance
    Schenker, Michael
    Grob, Jean -Jacques
    Chiarion-Sileni, Vanna
    Marquez-Rodas, Ivan
    Butler, Marcus O.
    Giacomo, Anna Maria Di
    Middleton, Mark R.
    Lutzky, Jose
    Cruz-Merino, Luis de la
    Arenberger, Petr
    Atkinson, Victoria
    Hill, Andrew G.
    Fecher, Leslie A.
    Millward, Michael
    Nathan, Paul D.
    Khushalani, Nikhil I.
    Queirolo, Paola
    Ritchings, Corey
    Lobo, Maurice
    Askelson, Margarita
    Tang, Hao
    Dolfi, Sonia
    Ascierto, Paolo A.
    Weber, Jeffrey
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3352 - 3361
  • [25] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
    Ascierto, P. A.
    Del Vecchio, M.
    Merelli, B.
    Gogas, H.
    Arance Fernandez, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J. J.
    Chiarion Sileni, V.
    Marquez-Rodas, I.
    Butler, M. O.
    Di Giacomo, A. M.
    Pe Benito, M.
    Soomro, R.
    Askelson, M.
    Weber, J. S.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S656 - S656
  • [26] Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience
    Sevillano Tripero, Alberto Rafael
    Ortiz, Carolina
    Lostes, Julia
    Bodet, Domingo
    Ferrandiz, Carla
    Bassas, Patricia
    Chiquillo, Paula
    Villacampa, Guillermo
    Vega-Cano, Kreina Sharela
    Garcia-Patos, Vicente
    Recio, Juan
    Munoz-Couselo, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
    Weber, Jeffrey S.
    Schadendorf, Dirk
    Del Vecchio, Michele
    Larkin, James
    Atkinson, Victoria
    Schenker, Michael
    Pigozzo, Jacopo
    Gogas, Helen
    Dalle, Stephane
    Meyer, Nicolas
    Ascierto, Paolo A.
    Sandhu, Shahneen
    Eigentler, Thomas
    Gutzmer, Ralf
    Hassel, Jessica C.
    Robert, Caroline
    Carlino, Matteo S.
    Di Giacomo, Anna Maria
    Butler, Marcus O.
    Munoz-Couselo, Eva
    Brown, Michael P.
    Rutkowski, Piotr
    Haydon, Andrew
    Grob, Jean-Jacques
    Schachter, Jacob
    Queirolo, Paola
    de la Cruz-Merino, Luis
    Haydon, Andrew
    Grob, Jean-Jacques
    Schachter, Jacob
    Queirolo, Paola
    De La Cruz-Merino, Luis
    van der Westhuizen, Andre
    Menzies, Alexander M.
    Re, Sandra
    Bas, Tuba
    de Pril, Veerle
    Braverman, Julia
    Tenney, Daniel J.
    Tang, Hao
    Long, Georgina, V
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 517 - +
  • [28] Stage III Melanoma: Pembrolizumab extends recurrence-free Survival
    Lichert, Frank
    AKTUELLE DERMATOLOGIE, 2018, 44 (10)
  • [29] Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings
    Reddy, Sangeetha M.
    Amaria, Rodabe N.
    Spencer, Christine N.
    Tetzlaff, Michael
    Reuben, Alexandre
    Andrews, Miles
    Wang, Linghua
    Woodman, Scott
    Zhu, Haifeng
    Blando, Jorge
    Vence, Luis
    Zhang, Shaojun
    Jiang, Hong
    Gopalakrishnan, Vancheswaran
    Hudgens, Courtney
    Wani, Khalida
    Tawbi, Hussein
    Diab, Adi
    Glitza, Isabella
    Patel, Sapna
    Hwu, Wen-Jen
    Wong, Michael
    Hwu, Patrick
    Cormier, Janice
    Lucci, Anthony
    Royal, Richard
    Lee, Jeffrey E.
    Simpson, Lauren
    Burton, Elizabeth M.
    Gershenwald, Jeffrey E.
    Ross, Merrick
    Allison, James
    Sharma, Padmanee
    Davies, Michael
    Wargo, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [30] Clinical predictors of survival in real world practice in stage IV melanoma
    Hu, Hsien-Pang
    Archer, Christine
    Yip, Desmond
    Peters, Geoffrey
    CANCER REPORTS, 2023, 6 (02)
12345